Top Page
Adaptimmune Therapeutics
(ADAPY)
Adaptimmune Therapeutics (ADAPY) vs. SPDR S&P 500 ETF (SPY)
Adaptimmune Therapeutics Business Overview & Revenue Model
Adaptimmune Therapeutics Financial Statement Overview
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Adaptimmune Therapeutics Technical Analysis
Adaptimmune Therapeutics Risk Analysis
Adaptimmune Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $40.94M | -1.03 | -277.74% | ― | 536.44% | 63.68% | |
| ― | $51.05M | -0.69 | ― | ― | 16.14% | 31.01% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $54.41M | -0.23 | -169.54% | ― | -100.00% | 29.21% | |
| ― | $38.93M | ― | -90.07% | ― | -32.55% | -15.83% | |
| ― | ― | ― | -1341.37% | ― | -53.61% | -93.14% | |
| ― | $36.06M | ― | -813.88% | ― | ― | 49.48% |
Adaptimmune Therapeutics Corporate Events
Study Overview: The SPEARHEAD-3 Pediatric Study, officially titled A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors, aims to evaluate the safety and efficacy of afamitresgene autoleucel in children aged 2-17 with advanced cancers. This study is significant as it targets rare pediatric cancers, potentially offering new treatment options.
Adaptimmune Therapeutics announced its decision to voluntarily delist its American Depositary Shares from the Nasdaq Capital Market, effective after October 27, 2025, and to deregister under the Securities Exchange Act of 1934. This strategic move, following a transaction with US WorldMeds, aims to reduce costs and support the company’s focus on maximizing value from its remaining assets. The delisting will result in the suspension of filing obligations and may lead to trading on the OTC Pink Limited Market, though there are no guarantees of continued trading.
The most recent analyst rating on (ADAP) stock is a Sell with a $0.46 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
On September 22, 2025, Adaptimmune Therapeutics received a notice from the Nasdaq Hearings Panel granting an exception period to comply with the Nasdaq Listing Rule requiring a minimum bid price of $1.00 per share. The company must meet this requirement by December 1, 2025, or face delisting from the Nasdaq Capital Market.
The most recent analyst rating on (ADAP) stock is a Sell with a $0.46 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
On September 11, 2025, Adaptimmune Therapeutics received a notice from Nasdaq indicating that its market value of listed securities had fallen below the $35 million minimum required for continued listing. The company has until March 10, 2026, to regain compliance, failing which its securities may be delisted from Nasdaq. The notice does not immediately affect the trading of its American Depositary Shares, but the company is exploring options to meet the compliance requirements.
The most recent analyst rating on (ADAP) stock is a Sell with a $0.46 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
On September 6, 2025, Adaptimmune Limited appointed Christopher Hill as Chief Financial Officer, effective September 10, 2025. Hill, with over a decade of experience in financial roles within life science companies, will manage the company’s accounting and finance functions as an independent contractor through a consulting agreement with CJH Financial Limited. This strategic appointment highlights Adaptimmune’s focus on strengthening its financial leadership as it continues to develop its therapeutic offerings.
The most recent analyst rating on (ADAP) stock is a Sell with a $0.46 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Adaptimmune Therapeutics announced changes in its executive team due to redundancy, affecting Gavin Wood, the Chief Financial Officer, and John Lunger, the Chief Patient Supply Officer. Mr. Wood’s employment will end on September 9, 2025, with a severance package including a year’s salary and other benefits, while Mr. Lunger’s termination is effective August 31, 2025, with similar severance terms. These changes reflect the company’s ongoing restructuring efforts, impacting its operational dynamics and potentially influencing stakeholder relations.
The most recent analyst rating on (ADAP) stock is a Sell with a $0.46 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
On August 15, 2025, Adaptimmune announced a separation agreement with Cintia Piccina, whose role as Chief Commercial Officer was terminated due to redundancy on August 8, 2025. As part of the agreement, Piccina will receive a severance payment equivalent to 12 months of her 2025 base salary, amounting to $473,800, and will have until January 30, 2032, to exercise her vested share options.
The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Adaptimmune Therapeutics plc, a company involved in the biotechnology industry, faced compliance issues with Nasdaq’s listing rules due to its American Depositary Shares trading below the required minimum bid price. On November 1, 2024, the company was notified of non-compliance and given until April 30, 2025, to resolve the issue. Despite an extension granted on May 1, 2025, to October 27, 2025, the company’s shares continued to fall, prompting Nasdaq to issue a delisting notice on August 14, 2025. Adaptimmune intends to request a hearing to present its compliance plan and seek additional time to meet the listing requirements, with its shares remaining on the Nasdaq Capital Market under the symbol ‘ADAP’ during the process.
The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Adaptimmune Therapeutics Plc is a cell therapy company that focuses on developing engineered T cell receptor (TCR) therapies to treat solid tumor cancers, aiming to improve cancer treatment experiences for patients. In its recent earnings report, Adaptimmune highlighted significant growth in its TECELRA sales, reporting a 150% increase in revenue compared to the previous quarter. The company also announced a strategic transaction with US WorldMeds for the sale of several cell therapies, which provided a $55 million upfront payment and potential future milestone payments. Key financial metrics revealed a decrease in total revenue due to the termination of a collaboration with Genentech, while product revenue saw an increase following TECELRA’s FDA approval. The company also reported a net loss, attributed to restructuring and reduced R&D expenses. Looking ahead, Adaptimmune is focused on maximizing the value of its remaining assets and ensuring sufficient liquidity to meet its operating requirements over the next year.
On August 7, 2025, Adaptimmune announced the termination of Dr. Elliot Norry as Chief Medical Officer, effective August 8, 2025, due to redundancy. Dr. Norry will receive a severance package including a year’s salary and healthcare coverage. Similarly, Dr. Joanna Brewer’s role as Chief Scientific Officer will end on August 31, 2025, with a similar severance arrangement. Gavin Wood’s termination as Chief Financial Officer, initially announced in December 2024, will also conclude on August 31, 2025, with a severance package including a year’s salary and a pro rata bonus. These changes reflect a strategic restructuring within the company.
The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
On July 31, 2025, Adaptimmune Therapeutics completed a significant transaction involving the sale of its cell therapy assets to USWM CT, LLC, receiving $55 million and potential future milestone payments. This transaction also allowed Adaptimmune to settle its $29.1 million debt with Hercules Capital, thereby improving its financial position and potentially impacting its future operations and market strategy.
The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
On July 27, 2025, Adaptimmune Therapeutics entered into an agreement to sell its cell therapy assets, including TECELRA, lete-cel, afami-cel, and uza-cel, to US WorldMeds for $55 million, with potential additional payments of up to $30 million based on milestone achievements. This transaction is part of a broader restructuring plan by Adaptimmune to maximize value from its remaining assets and involves significant workforce reductions. The restructuring will see key executives depart and is expected to incur pre-tax costs of approximately $7-8 million. The transaction aims to ensure the continued availability of TECELRA to patients and support the development of other therapies by US WorldMeds.
The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.